Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Type of Cancer
Leukemia

Phase

Division (Location)

Study ID

NCT#

Brief Description
Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.